Fig. 1From: A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancerStudy design. a Framework for the dose-escalation and dose-expansion study of dalpiciclib. b Dosing and assessment schema. DLT, dose-limiting toxicity; PD, progressive diseaseBack to article page